Study #2022-0028
Post-transplant maintenance therapy with Isatuximab plus Lenalidomide for high-risk multiple Myeloma patients
MD Anderson Study Status
Enrolling
Treatment Agent
Isatuximab, lenalidomide
Description
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase II
Physician name:
Muzaffar Qazilbash
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-888-704-1252
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.